PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

AcuFocus raises USD66m in financing round led by KKR

AcuFocus, a privately held ophthalmic medical device company, has secured a private investment of approximately USD66 million in a financing round led by KKR.

AcuFocus develops and markets breakthrough small aperture technologies for the improvement of near vision.
 
The investment follows several key milestones for AcuFocus, including the controlled commercial launch of its flagship product, the KAMRA corneal inlay, in the US and CE Mark approval for its second product, the IC-8 intraocular lens.
 
Both technologies use the small aperture effect to treat presbyopia, the natural loss of near vision that eventually affects everyone over the age of 40, as well as cataracts, the clouding of the eye’s natural lens.
 
The financing round led by KKR will allow AcuFocus to accelerate its commercialisation plans for the KAMRA inlay and IC-8 lens as well as further advances in research and development projects that continue to leverage its small aperture expertise.
 
“We are honoured that KKR has chosen to make AcuFocus its first investment in the ophthalmic space,” says Bill Link, AcuFocus chairman of the board. “Through this partnership, and the continued support of our current investors, we look forward to driving the company into a global market leadership position in presbyopia and cataract surgery.”
 
“This investment is a critical catalyst for the company,” says Al Waterhouse, AcuFocus president and chief operating officer. “KKR’s confidence in our technology, along with its track record in successfully scaling businesses, will allow us to execute aggressively on growth plans to bring our disruptive small aperture technologies to full commercialisation.”
 
“AcuFocus is a unique ophthalmic device platform with a differentiated set of products, strong patient outcomes and an accomplished management team,” says Arjun Arora, principal on KKR’s Americas healthcare investing team. “We are confident that these technologies will play an important role in the way in which surgeons treat presbyopia and cataracts. We look forward to supporting the management and employees of AcuFocus in bringing these products to patients worldwide and accelerating the company’s growth plans.”

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured